SG11202005985PA - Benzamide compounds - Google Patents
Benzamide compoundsInfo
- Publication number
- SG11202005985PA SG11202005985PA SG11202005985PA SG11202005985PA SG11202005985PA SG 11202005985P A SG11202005985P A SG 11202005985PA SG 11202005985P A SG11202005985P A SG 11202005985PA SG 11202005985P A SG11202005985P A SG 11202005985PA SG 11202005985P A SG11202005985P A SG 11202005985PA
- Authority
- SG
- Singapore
- Prior art keywords
- benzamide compounds
- benzamide
- compounds
- Prior art date
Links
- 150000003936 benzamides Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862615857P | 2018-01-10 | 2018-01-10 | |
PCT/US2019/012695 WO2019139899A1 (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005985PA true SG11202005985PA (en) | 2020-07-29 |
Family
ID=67218673
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005985PA SG11202005985PA (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
SG11202005785XA SG11202005785XA (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
SG11202005784YA SG11202005784YA (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005785XA SG11202005785XA (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
SG11202005784YA SG11202005784YA (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
Country Status (15)
Country | Link |
---|---|
US (6) | US11344546B2 (en) |
EP (3) | EP3737681A4 (en) |
JP (4) | JP2021510163A (en) |
KR (3) | KR20200108301A (en) |
CN (5) | CN118084905A (en) |
AR (4) | AR114998A1 (en) |
AU (4) | AU2019207608B2 (en) |
BR (3) | BR112020014151A2 (en) |
CA (3) | CA3087261A1 (en) |
IL (3) | IL275761A (en) |
MX (4) | MX2020007388A (en) |
RU (2) | RU2020120928A (en) |
SG (3) | SG11202005985PA (en) |
TW (4) | TWI829664B (en) |
WO (4) | WO2019139899A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
JP7085566B2 (en) | 2017-04-18 | 2022-06-16 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | Apoptosis inducer |
JP2021510163A (en) | 2018-01-10 | 2021-04-15 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Benzamide compound |
EP3972966A4 (en) * | 2019-07-10 | 2023-04-26 | Recurium IP Holdings, LLC | Bcl-2 protein inhibitors |
AU2020311369A1 (en) * | 2019-07-10 | 2021-12-23 | Recurium Ip Holdings, Llc | Nanoparticle formulation of Bcl-2 inhibitor |
US20230041515A1 (en) | 2019-12-06 | 2023-02-09 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
KR20220119420A (en) * | 2019-12-20 | 2022-08-29 | 리커리엄 아이피 홀딩스, 엘엘씨 | Combination |
WO2021127044A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
JP2023508324A (en) * | 2019-12-20 | 2023-03-02 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | combination |
EP4069234A4 (en) * | 2019-12-20 | 2024-01-03 | Recurium IP Holdings, LLC | Combinations |
IL295554A (en) * | 2020-02-21 | 2022-10-01 | Recurium Ip Holdings Llc | Difluoromethyl iodo compounds and methods |
US20230167105A1 (en) * | 2020-04-28 | 2023-06-01 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
EP4106760A4 (en) * | 2020-05-07 | 2024-03-27 | Recurium IP Holdings, LLC | Combinations |
MX2022014468A (en) * | 2020-05-19 | 2023-02-09 | Recurium Ip Holdings Llc | Treatment for amyloidosis. |
CN116744919A (en) * | 2020-10-16 | 2023-09-12 | 里科瑞尔姆Ip控股有限责任公司 | Combination of BCL-2 inhibitors and chemotherapeutic agents |
WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
CN113143930B (en) * | 2021-04-08 | 2023-05-30 | 深圳湾实验室 | Use of compound in preparing SARS-Cov-2E protein inhibitor |
CN113816889B (en) * | 2021-10-11 | 2023-08-22 | 中国药科大学 | 4-sulfimide-1H-pyrrole Mcl-1 inhibitor and anti-tumor medical application thereof |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003096461A (en) | 2001-09-25 | 2003-04-03 | Fuji Photo Film Co Ltd | Liquid-crystal composition and liquid crystal element using the same |
DE10217814A1 (en) | 2002-04-22 | 2003-11-13 | Ibfb Pharma Gmbh | New tricyclic mercaptans, processes for their preparation and their use as medicines |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005079803A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
JP4628140B2 (en) | 2005-03-03 | 2011-02-09 | 富士フイルム株式会社 | Cellulose acylate film, polarizing plate and liquid crystal display device |
AU2006297853B2 (en) | 2005-05-12 | 2010-08-19 | AbbVie Global Enterprises Ltd. | Apoptosis promoters |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
EP2061772A4 (en) | 2006-09-11 | 2011-06-29 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
CN101535280B (en) | 2006-11-15 | 2012-06-27 | 健泰科生物技术公司 | Arylsulfonamide compounds |
US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
WO2008070663A2 (en) | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
UA108193C2 (en) | 2008-12-04 | 2015-04-10 | APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES | |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP3666758A1 (en) * | 2008-12-05 | 2020-06-17 | AbbVie Inc. | Process for the preparation of a sulfonamide derivative |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
AU2010204555B2 (en) | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
DK2435432T6 (en) | 2009-05-26 | 2023-12-18 | Abbvie Ireland Unlimited Co | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI532484B (en) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | Solid dispersions containing an apoptosis-promoting agent |
MX2011013797A (en) | 2009-06-18 | 2012-01-30 | Abbott Lab | Stable nanoparticulate drug suspension. |
WO2010148422A1 (en) | 2009-06-25 | 2010-12-29 | Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for treating parasitic infestations |
MX2012002059A (en) | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. |
CN101798292A (en) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | Method for preparing novel Bc1-2 protein inhibitor derived from ABT-263 |
TWI520960B (en) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
UA113500C2 (en) | 2010-10-29 | 2017-02-10 | MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
EP2638007A2 (en) | 2010-11-11 | 2013-09-18 | Redx Pharma Limited | Drug derivatives |
DK2642999T3 (en) | 2010-11-23 | 2017-01-09 | Abbvie Ireland Unlimited Co | METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS |
JP5998152B2 (en) | 2011-01-25 | 2016-09-28 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | BCL-2 / BCL-XL inhibitor and therapeutic method using the same |
WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
CA2897055C (en) | 2013-01-16 | 2021-04-20 | The Regents Of The University Of Michigan | Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
EP4019491A1 (en) | 2013-03-13 | 2022-06-29 | AbbVie Ireland Unlimited Company | Process for preparing a synthetic intermediate useful in the preparation of an apoptosis-inducing agent |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP2999470B1 (en) | 2013-05-22 | 2017-08-16 | Children's Hospital Medical Center | Combination therapy for mds |
AU2014269144B2 (en) | 2013-05-24 | 2019-10-31 | Mark Barry HAMPTON | Bioactive compounds |
JP6730183B2 (en) | 2013-07-12 | 2020-07-29 | ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー | Cystobactamides |
WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
CN105012318B (en) | 2014-04-17 | 2020-02-11 | 沈华浩 | Application of sulfonamide compound in airway chronic inflammatory diseases |
CN104131034B (en) | 2014-06-19 | 2017-04-05 | 中山大学 | A kind of chimeric vector and its preparation method and application |
WO2016025652A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods |
CA2961605C (en) * | 2014-09-17 | 2023-01-10 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
UY36391A (en) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
TW201639573A (en) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | Combination therapies for treating cancers |
JP2018508569A (en) | 2015-02-06 | 2018-03-29 | ユニティ バイオテクノロジー インコーポレイテッド | Compounds and uses in the treatment of aging-related conditions |
WO2016131100A1 (en) | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
US20180161347A1 (en) * | 2015-04-20 | 2018-06-14 | Mayo Foundation For Medical Education And Research | Methods and materials for killing hiv infected cells |
UA124617C2 (en) | 2015-05-26 | 2021-10-20 | Ф. Хоффманн-Ля Рош Аг | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor |
GB201513481D0 (en) | 2015-07-30 | 2015-09-16 | Univ Manchester | Inhibitor compounds |
US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
CN106608895A (en) | 2015-10-21 | 2017-05-03 | 苏州国匡医药科技有限公司 | BCL-2 selective inhibitor with sugar ring structure and application thereof |
US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
CN106957315B (en) | 2016-01-08 | 2019-08-13 | 中国人民解放军第二军医大学 | N- replaces benzenesulfonyl-azaindole oxybenzamide class compound and its prepares the purposes of drug |
AU2017206731A1 (en) | 2016-01-11 | 2018-08-02 | Merrimack Pharmaceuticals, Inc. | Inhibiting B-cell lymphoma 2 (Bcl-2) and related proteins |
WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
WO2017184995A1 (en) | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
CN109475567A (en) | 2016-06-09 | 2019-03-15 | 布兰克生物股份有限公司 | Treatment payload based on silanol |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
CN106565706B (en) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | A kind of sulfamide derivative and its application in pharmacy |
CN106749233B (en) | 2016-11-24 | 2020-04-21 | 中山大学 | Sulfonamide derivatives and application thereof |
EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
WO2018146506A1 (en) | 2017-02-10 | 2018-08-16 | Universitat Politècnica De València | Therapeutic derivatives |
CN107089981A (en) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | A kind of inhibitor Venetoclax of BCL 2 synthetic method |
JP2021510163A (en) | 2018-01-10 | 2021-04-15 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Benzamide compound |
BR112020022092A2 (en) | 2018-04-29 | 2021-02-02 | Beigene, Ltd. | compounds, method for treating unregulated apoptotic diseases and pharmaceutical composition |
SG11202101955SA (en) | 2018-09-18 | 2021-03-30 | Signalchem Lifesciences Corp | Combination therapy for treating blood cancer |
-
2019
- 2019-01-08 JP JP2020538644A patent/JP2021510163A/en active Pending
- 2019-01-08 CA CA3087261A patent/CA3087261A1/en active Pending
- 2019-01-08 SG SG11202005985PA patent/SG11202005985PA/en unknown
- 2019-01-08 WO PCT/US2019/012695 patent/WO2019139899A1/en unknown
- 2019-01-08 SG SG11202005785XA patent/SG11202005785XA/en unknown
- 2019-01-08 KR KR1020207022537A patent/KR20200108301A/en unknown
- 2019-01-08 AU AU2019207608A patent/AU2019207608B2/en active Active
- 2019-01-08 BR BR112020014151-8A patent/BR112020014151A2/en not_active Application Discontinuation
- 2019-01-08 CN CN202410225032.5A patent/CN118084905A/en active Pending
- 2019-01-08 WO PCT/US2019/012704 patent/WO2019139902A1/en unknown
- 2019-01-08 RU RU2020120928A patent/RU2020120928A/en unknown
- 2019-01-08 EP EP19738858.0A patent/EP3737681A4/en not_active Withdrawn
- 2019-01-08 WO PCT/US2019/012699 patent/WO2019139900A1/en active Application Filing
- 2019-01-08 EP EP19738996.8A patent/EP3740487A4/en active Pending
- 2019-01-08 CA CA3087262A patent/CA3087262A1/en active Pending
- 2019-01-08 US US16/957,862 patent/US11344546B2/en active Active
- 2019-01-08 CN CN202410225030.6A patent/CN118084904A/en active Pending
- 2019-01-08 MX MX2020007388A patent/MX2020007388A/en unknown
- 2019-01-08 AU AU2019207616A patent/AU2019207616A1/en not_active Abandoned
- 2019-01-08 US US16/957,865 patent/US11590126B2/en active Active
- 2019-01-08 CN CN201980015923.5A patent/CN111788203A/en active Pending
- 2019-01-08 SG SG11202005784YA patent/SG11202005784YA/en unknown
- 2019-01-08 KR KR1020207022538A patent/KR20200108302A/en not_active Application Discontinuation
- 2019-01-08 BR BR112020014169-0A patent/BR112020014169A2/en unknown
- 2019-01-08 AU AU2019207611A patent/AU2019207611A1/en not_active Abandoned
- 2019-01-08 RU RU2020120929A patent/RU2020120929A/en unknown
- 2019-01-08 EP EP19738922.4A patent/EP3737672A4/en not_active Withdrawn
- 2019-01-08 MX MX2020007392A patent/MX2020007392A/en unknown
- 2019-01-08 BR BR112020014160-7A patent/BR112020014160A2/en not_active Application Discontinuation
- 2019-01-08 MX MX2020007014A patent/MX2020007014A/en unknown
- 2019-01-08 CA CA3087263A patent/CA3087263A1/en active Pending
- 2019-01-08 CN CN201980015896.1A patent/CN111801320A/en active Pending
- 2019-01-08 JP JP2020538691A patent/JP7355741B2/en active Active
- 2019-01-08 KR KR1020207022443A patent/KR20200108298A/en unknown
- 2019-01-08 US US16/957,861 patent/US11318134B2/en active Active
- 2019-01-08 WO PCT/US2019/012719 patent/WO2019139907A1/en unknown
- 2019-01-08 CN CN201980015882.XA patent/CN111801327B/en active Active
- 2019-01-08 JP JP2020538692A patent/JP2021510165A/en active Pending
- 2019-01-10 TW TW108101048A patent/TWI829664B/en active
- 2019-01-10 TW TW108101046A patent/TW201934538A/en unknown
- 2019-01-10 AR ARP190100053A patent/AR114998A1/en unknown
- 2019-01-10 TW TW108101047A patent/TW201930317A/en unknown
- 2019-01-10 AR ARP190100050A patent/AR114948A1/en unknown
- 2019-01-10 AR ARP190100052A patent/AR114950A1/en unknown
- 2019-01-10 TW TW108101045A patent/TW201934550A/en unknown
- 2019-01-10 AR ARP190100051A patent/AR114949A1/en unknown
-
2020
- 2020-06-30 IL IL275761A patent/IL275761A/en unknown
- 2020-06-30 IL IL275762A patent/IL275762A/en unknown
- 2020-06-30 IL IL275763A patent/IL275763A/en unknown
- 2020-07-13 MX MX2023009185A patent/MX2023009185A/en unknown
-
2022
- 2022-03-28 US US17/656,726 patent/US11813259B2/en active Active
-
2023
- 2023-05-26 US US18/202,622 patent/US11813260B1/en active Active
- 2023-09-20 US US18/471,017 patent/US20240180899A1/en active Pending
- 2023-09-21 JP JP2023156385A patent/JP2024001052A/en active Pending
-
2024
- 2024-06-06 AU AU2024203833A patent/AU2024203833A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275761A (en) | Benzamide compounds | |
GB201805174D0 (en) | Compounds | |
GB201810092D0 (en) | Compounds | |
GB201801355D0 (en) | Compounds | |
GB201807924D0 (en) | Compounds | |
GB201810581D0 (en) | Compounds | |
GB201814151D0 (en) | Compounds | |
GB201808093D0 (en) | Compounds | |
GB201809102D0 (en) | Compounds | |
GB201817083D0 (en) | Compounds | |
GB201812382D0 (en) | Compounds | |
GB201810071D0 (en) | Compounds | |
GB201803340D0 (en) | Compounds | |
GB201818651D0 (en) | Compounds | |
GB201818649D0 (en) | Compounds | |
GB201814167D0 (en) | Compounds | |
GB201801128D0 (en) | Compounds | |
GB201801130D0 (en) | Compounds | |
GB201818927D0 (en) | Compounds | |
GB201818698D0 (en) | Compounds | |
GB201818410D0 (en) | Compounds | |
GB201817342D0 (en) | Compounds | |
GB201817303D0 (en) | Compounds | |
GB201817291D0 (en) | Compounds | |
GB201817292D0 (en) | Compounds |